Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Neoleukin Therapeutics (NASDAQ: NLTX) announced that CEO Jonathan Drachman will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The on-demand presentation will be accessible starting January 10 at 7:00 a.m. ET via Neoleukin's investors section. Neoleukin focuses on developing next-generation immunotherapies for cancer and autoimmune diseases using de novo protein design technology. Its lead product, NL-201, is an IL-2 and IL-15 agonist aimed at enhancing therapeutic efficacy.

Positive

• Lead product candidate NL-201 designed to improve tolerability and activity.
• Utilization of advanced de novo protein design technology for superior therapeutic outcomes.

Negative

• None.

SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.

The webcast presentation can be accessed from the investors section of the Neoleukin website at http://investor.neoleukin.com/events. An archived replay will also be available on the company website for at least 30 days following the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Safe Harbor / Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the therapeutic properties and potential of the company’s de novo protein design technology, the results of the clinical trial for NL-201, and planned clinical and development activities and timelines. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company’s cash forecasts, the company’s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company’s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin’s business and its financial results are detailed under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

FAQ

When is the H.C. Wainwright BIOCONNECT Virtual Conference for Neoleukin (NLTX)?

The conference takes place from January 10-13, 2022.

Where can I access the Neoleukin (NLTX) conference presentation?

The presentation can be accessed from the investors section of the Neoleukin website starting January 10, 2022, at 7:00 a.m. ET.

What is the lead product of Neoleukin Therapeutics (NLTX)?

Neoleukin's lead product candidate is NL-201, an IL-2 and IL-15 agonist.